Abstract
A 46-year-old woman had an episode of atrial fibrillation during infusion of docetaxel as adjuvant chemotherapy for an infiltrating ductal carcinoma of the breast. All cardiological tests performed before treatment were normal and there was no evidence of thyroid dysfunction nor any objective or anamnestic data indicating acute or chronic cardiovascular disease. None of the drugs administered has ever shown any proarrhythmic activity. In controlled clinical trials docetaxel was found to have a very low cardiotoxicity.
MeSH terms
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Agents, Phytogenic / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Atrial Fibrillation / chemically induced*
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / surgery
-
Carcinoma, Ductal, Breast / drug therapy
-
Carcinoma, Ductal, Breast / surgery
-
Chemotherapy, Adjuvant / adverse effects
-
Cyclophosphamide / administration & dosage
-
Docetaxel
-
Epirubicin / administration & dosage
-
Female
-
Fluorouracil / administration & dosage
-
Humans
-
Middle Aged
-
Paclitaxel / administration & dosage
-
Paclitaxel / adverse effects*
-
Paclitaxel / analogs & derivatives*
-
Taxoids*
-
Treatment Outcome
Substances
-
Antineoplastic Agents, Phytogenic
-
Taxoids
-
Docetaxel
-
Epirubicin
-
Cyclophosphamide
-
Paclitaxel
-
Fluorouracil